Concepedia

Publication | Open Access

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

DOIFull Paper Access

193

Citations

29

References

2009

Year

Gary Lichtenstein, Robert H. Diamond, Carrie Wagner, Adedigbo A. Fasanmade, A. Olson, Colleen Marano, Jewel Johanns, Yinghua Lang, William J. Sandborn
Alimentary Pharmacology & Therapeutics

Abstract

Concomitant immunomodulators did not improve efficacy or pharmacokinetics in IBD patients who received maintenance infliximab.

References

YearCitations

Page 1